199 related articles for article (PubMed ID: 15314586)
1. Telithromycin (Ketek) for respiratory infections.
Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
[No Abstract] [Full Text] [Related]
2. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
3. Telithromycin.
Spiers KM; Zervos MJ
Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
[TBL] [Abstract][Full Text] [Related]
4. [Telithromycin].
Calbo E; Garau J
Rev Esp Quimioter; 2004 Mar; 17(1):15-25. PubMed ID: 15201919
[No Abstract] [Full Text] [Related]
5. Telithromycin (Ketek) for community-acquired respiratory tract infections.
Wimett L; Laustsen G
Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
[No Abstract] [Full Text] [Related]
6. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
7. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
Reinert RR
J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
10. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
11. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ
Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of ketoride antibiotics, telithromycin in treatment of respiratory tract infections (discussion)].
Kohno S; Watanabe A; Aoki N; Niki Y
Jpn J Antibiot; 2003 Dec; 56(6):531-45. PubMed ID: 15007871
[No Abstract] [Full Text] [Related]
15. [Telithromycin].
Benes J
Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
[TBL] [Abstract][Full Text] [Related]
16. Hidden epidemic of macrolide-resistant pneumococci.
Klugman KP; Lonks JR
Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
[TBL] [Abstract][Full Text] [Related]
17. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
[TBL] [Abstract][Full Text] [Related]
18. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland.
Meyer Sauteur PM; Bleisch B; Voit A; Maurer FP; Relly C; Berger C; Nadal D; Bloemberg GV
Swiss Med Wkly; 2014; 144():w14041. PubMed ID: 25254315
[No Abstract] [Full Text] [Related]
19. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
20. Induction of telithromycin resistance in Streptococcus pneumoniae.
Kaieda S; Okitsu N; Yano H; Hosaka Y; Nakano R; Okamoto R; Takahashi H; Inoue M
J Antimicrob Chemother; 2003 Oct; 52(4):736-7. PubMed ID: 12951334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
